These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11346877)

  • 21. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
    Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
    Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
    Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
    Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
    Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
    J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor.
    Olieman AF; van Ginkel RJ; Hoekstra HJ; Mooyaart EL; Molenaar WM; Koops HS
    Ann Surg Oncol; 1997 Jan; 4(1):64-9. PubMed ID: 8985519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
    Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
    Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression.
    Komdeur R; Molenaar WM; Zwart N; Hoekstra HJ; van den Berg E; van der Graaf WT
    Anticancer Res; 2004; 24(1):291-5. PubMed ID: 15015610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperthermic isolated limb perfusion for extremity sarcomas.
    Kim CJ; Puleo C; Letson GD; Reintgen D
    Cancer Control; 2001; 8(3):269-73. PubMed ID: 11378653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
    Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
    Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
    Diestra JE; Condom E; Del Muro XG; Scheffer GL; Pérez J; Zurita AJ; Muñoz-Seguí J; Vigués F; Scheper RJ; Capellá G; Germà-Lluch JR; Izquierdo MA
    J Urol; 2003 Oct; 170(4 Pt 1):1383-7. PubMed ID: 14501774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.
    Eggermont AM; ten Hagen TL
    Curr Oncol Rep; 2001 Jul; 3(4):359-67. PubMed ID: 11389822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
    van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
    J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.
    Grabellus F; Kraft C; Sheu SY; Ebeling P; Bauer S; Lendemans S; Schmid KW; Taeger G
    Ann Surg Oncol; 2009 Mar; 16(3):676-86. PubMed ID: 19130134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
    Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
    Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.